Rational Reagent Tactics for Optimizing Biomarker Analysis

Ed Hamdeh, PD. Shalaka Samant, PhD. • July 21, 2020
Rational Reagent Tactics for Optimizing Biomarker Analysis

Rational Reagent Tactics for Optimizing Biomarker Analysis

The selection or rational design of a linker to join fusion protein domains is an important, under-explored area in recombinant fusion protein technology

Background

Sourcing and applying multiple proteins into a specific biomarker assay involves a variety of moving pieces. Particularly during discovery stage research, where molecules of interest are constantly changing relative to hit identification. In other words, protein reagents play a significantly underrated role in developing early assays for biomarker analysis.

This article explores key material components and common oversight in recombinant protein approaches to help demonstrate factors effecting assay design. Additionally, we present a set of rational tactics for optimizing biomarker analysis through the procurement and criteria of laboratory/assay reagents.

Topics Covered

Insight on various aspects of the biomarker workflow, such as:

  • Expression Hosts
  • Tag/labeling
  • Qualifying quality
  • Critical reagents development relative to vendor consistency

Take the next step in optimizing your biomarker analysis.


Download the full whitepaper now.

October 23, 2025
Discover kbDNA’s rapid workflow for repurifying rituximab biosimilars to high-purity standards—featuring SEC overlays, gel schematics, and SOPs.
Glowing blue and orange DNA strand against a dark background.
By Ed Hamdeh October 13, 2025
Unfiltered truths, hidden risks, and real data behind life sciences R&D in North America. Discover the facts nobody else is sharing—read the full report now
A green and purple background with a pattern of flowers on it.
By Vaibhav Shah May 17, 2025
This article explores the complexities of biosimilars, including their development process, regulatory challenges, economic impact, and future prospects. It highlights the potential of biosimilars to reduce healthcare costs and increase patient access to biologic therapies, providing valuable insights for biopharmaceutical and academic researchers.